Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common supplement boost cancer therapy? new trial tests taurine with immunotherapy for stomach cancer.

NCT ID NCT06128252

Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the supplement taurine to a standard treatment (immunotherapy drug serplulimab plus chemotherapy) can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 96 adults whose tumors have a specific marker (PD-L1 positive) will be randomly assigned to receive either the taurine combination or the standard treatment alone. The main goal is to see if more tumors completely disappear after treatment with the taurine combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 96 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-75 years old, no gender limitation; 2. Pathologically confirmed gastric or gastroesophageal junction adenocarcinoma with cTNM stage II/III，T≥3, N ≥0, M=0； 3. Expected survival of ≥ 3 months; 4. The tumor specimens were PD-L1 positive (CPS ≥ 1)； 5. There is a measurable lesion with the possibility of radical R0 resection after evaluation by doctors； 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; 7. Patients informed about the purpose and course of the study and provided a written consent to participate. Exclusion Criteria: 1. Use of taurine agent within 1 month prior to the first dose of study treatment and throughout the study; 2. Patients with positive HER-2； 3. Patients with gastrointestinal obstruction or active bleeding in the gastrointestinal tract, as well as perforation and dysphagia; 4. Patients with severe heart, lung, liver, kidney, endocrine, hematopoietic system or psychiatric diseases were considered not suitable for the study group; 5. Human immunodeficiency virus (HIV) infection or known acquired immune deficiency syndrome (AIDS) or autoimmune disease or immunosuppressant use； 6. There are patients who may increase the risk of participating in the study and study medication, or other severe, acute and chronic diseases, and are not suitable for participating in the clinical study according to the judgment of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University

    RECRUITING

    Nanjing, Jiangsu, 210008, China

  • Army Specialty Medical Center of PLA (Daping Hospital)

    RECRUITING

    Chongqing, 400042, China

  • Cancer Hospital Affiliated to Xinjiang Medical University

    RECRUITING

    Ürümqi, Xinjiang Uygur Autonomous Region, 830000, China

  • Fudan University Shanghai Cancer Center (FUSCC)

    RECRUITING

    Shanghai, 200032, China

  • Shaanxi Provincial People's Hospital

    RECRUITING

    Xi'an, Shaanxi, 710068, China

  • Tang-Du Hospital

    RECRUITING

    Xi'an, Shaanxi, 710038, China

  • The First Affiliated Hospital of Army Medical University (Southwest Hospital)

    RECRUITING

    Chongqing, 400038, China

  • The First Affiliated Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110001, China

  • The Second Affilated Hospital Of Xi'an Jiaotong University (Xibei Hospital)

    RECRUITING

    Xi'an, Shaanxi, China

  • The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)

    RECRUITING

    Chongqing, 400037, China

  • The Third People's Hospital of Chengdu

    RECRUITING

    Chengdu, Sichuan, China

  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

  • Xi 'an International Medical Center Hospital

    RECRUITING

    Xi'an, Shaanxi, 710100, China

  • Xi'an NO.3 hospital

    RECRUITING

    Xi'an, Shaanxi, China

  • Xi-jing Hospital

    RECRUITING

    Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.